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Examination of intraductal papillary mucinous neoplasms of pancreas and their 
association with extrapancreatic malignancies 
 
Objectives: The primary objective of the thesis is to assess the prevalence and the 
incidence of extrapancreatic malignancies (EPMs) in a cohort of Italian patients 
diagnosed with intraductal papillary mucinous neoplasms (IMPNs) of pancreas, and to 
identify the risk factors for their occurrence. The secondary objective is to assess an 
association between pancreatic IPMN and selected single nucleotide polymorphisms 
(SNPs) within 8q24 region of human genome. The tertiary objective of the thesis is to 
assess whether patients with pancreatic IPMNs have an increased propensity to develop 
colorectal adenomas.  
Methods: In order to meet the objectives three separate studies were conducted: the 
hospital-based multicentric study, the genetic association study and the colonoscopic 
case-control study.  
The hospital-based multicentric study was conducted in Italy from January 2010 to 
January 2011 in eight participating centers. Three hundred ninety IPMN cases were 
included in the study and screened for EPMs. EPMs were grouped according to time of 
their diagnosis as previous, synchronous (both prevalent) and metachronous (incident). 
The distribution of demographics, medical history and lifestyle habits was assessed 
among cases. The observed/expected (O/E) ratio of prevalent EPMs was calculated.  
The genetic association study was performed on 117 IPMN cases and 231 age and 
gender matched controls. Cases were enrolled at the Digestive Endoscopy Unit, 
Policlinico Agostino Gemelli, Rome, Italy with either a prevalent or incident IPMN 
diagnosis, diagnosed from January 2010 to June 2011. Status of selected SNPs 
(rs6983267, rs6993464, rs7014346, rs10505477) was determined using a StepOne Real-
time PCR system (Applied Biosystems) and TaqMan SNP Genotyping Assay ™ 40X. 
Unconditional multiple logistic regression models were used to estimate odds ratios 
(ORs) and 95% confidence intervals (CIs) for the association of selected SNPs and 
IPMNs. 
  
The colonoscopic case–control study was conducted at Catholic University and 
University Sapienza, Rome, Italy on 122 cases and 246 controls. Cases were patients 
with IPMNs without history of colorectal cancer, who underwent screening 
colonoscopy for the first time. Controls were individuals who underwent first time 
colonoscopy for screening or evaluation of non-specific abdominal symptoms. 
Prevalence of colon polyps and/or colorectal cancer was determined using colonoscopy 
findings. Chi-square and Fisher tests were used to compare the distributions of 
categorical variables between patients with IPMNs and control subject.    
Results: Ninety-seven EPMs were diagnosed in 92 patients (23.6%) in hospital-based 
multicentric study. Among them 78 (80.4%) were previous, 14 (14.4%) were 
synchronous, and 5 (5.2%) were metachronous. O/E ratios for prevalent EPMs were 
significantly increased for colorectal carcinoma (2.26, CI 95%: 1.17-3.96), renal cell 
carcinoma (6.00, CI 95%: 2.74-11.39) and thyroid carcinoma (5.56, CI 95%: 1.80-
12.96). Increased age, heavy cigarette smoking, alcohol consumption and 1st-degree 
family history of gastric cancer were significant risk factors for EPMs, while 1st-degree 
family history of colorectal carcinoma was borderline. Genetic association study 
showed no significant association between IPMN and SNPs rs6983267, rs6993464, 
rs7014346, rs10505477. In colonoscopic case-control study, colorectal polyps were 
found in 52 cases (42.6%) and 79 controls (32.1%) (p<0.05). In 29 cases (23.8%) and 
57 controls (23.2%) histological examination disclosed adenomatous polyps (p=0.90). 
There was no difference between the groups in relation to presence of polyps with low-
grade (19.7% vs. 19.8%, p=0.98) and high-grade dysplasia (4.9% vs. 4.5%, p=0.85).  
Conclusions: We report an increased prevalence of EPMs in Italian patients with 
IPMN, especially for colorectal carcinoma, renal cell and thyroid cancers. A systematic 
surveillance of IPMN cases for such cancer types would be advised. Patients with 
IPMN do not have a higher prevalence of SNPs rs6983267, rs6993464, rs7014346, 
rs10505477 in human chromosomal region 8q24 in respect to control population. 
However further research is needed in order to examine if other SNPs in the region are 
associated with IPMN. Patients with IPMNs are not in an increased risk for 
development of adenomatous colorectal polyps. 
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Ispitivanje intraduktalnih papilarnih mucinoznih neoplazmi pankreasa i njihove 
povezanosti sa ekstrapankreasnim malignitetima 
Ciljevi: Primarni cilj doktorske disertacije je utvrditi prevalenciju i incidenciju 
ekstrapankreasnih maligniteta (EPM) u kohorti italijanskih pacijenata sa intraduktalnim 
papilarnim mucinoznim neoplazmama (IPMN) pankreasa i identifikovati faktore rizika 
za njihov nastanak. Sekundarni cilj doktroske disertacije je utvrditi da li je prisustvo 
IPMN udruženo sa prisustvom odabranih genetskih “single-nucleotide” polimorfizama 
(SNP) u 8q24 regionu humanog genoma. Tercijarni cilj doktorske disertacije je utvrditi 
da li pacijenti sa IPMN imaju značajno više kolorektalih adenoma u odnosu na opštu 
populaciju. 
Metode: Kako bi se ispunili navedeni ciljevi doktorske disertacije sprovedene su tri 
odvojene studije: multicentrična bolnička studija, studija genetske asocijacije i 
kolonoskopska studija slučajeva i kontrola.  
Multicentrična bolnička studija sprovedena je u osam bolničkih centara u Italiji u period 
od janura 2010 do januara 2011. Tri stotine devedeset pacijenata sa IPMN uključeni su 
u studiju i ispitani na prisustvo EPM. EPM su u odnosu na vreme otkrivanja grupisani 
na prethodne i sinhrone (koji zajedno čine prevalentne) i metahrone. Dobijeni podatci 
iskorišćeni su kako bi se izračunao odnos otkrivenih i očekivanih EPM (O/E odnos). 
Pacijenti sa i bez EPM su upoređeni u odnosu na demografske karakteristike, životne 
navike i prethodnu istoriju bolesti.  
Studija genetske asocijacije sprovedena je na 177 IPMN slučajeva i 231 kontrola 
uparenih po polu i starosti. Novotkriveni slučajevi IPMN, kao i oni koji su imali 
zakazane kontrolne preglede u Službi za digestivnu endoskopiju Poliklinike Agostino 
Gemelli, Rim, Italija  u period od januara 2010 do juna 2011 uključeni su u studiju. 
Status odabranih SNP (rs6983267, rs6993464, rs7014346, rs10505477) određivan je uz 
pomoć “StepOne Real-time PCR” (Applied Biosystems) i “TaqMan SNP Genotyping 
Assay ™ 40X” sistema. Bezuslovni multivarijantni logisticki regresioni model je 
korisćen za procenu odnosa šansi (OR) i 95%-og intervala poverenja (95% CI) 
asocijacije odabranih SNP sa IPMN.  
  
Kolonoskopska studija slučajeva i kontrola sprovedena je na Katoličkom Univerzitetu i 
na Univerzitetu “Sapienza”, Rim, Italija na 122 slučaja i 246 kontrola. Slučajevi su bili 
pacijenti sa IPMN bez prethodne istorije kolorektalnog karcinoma, podvrgnuti 
kolonoskopiji po prvi put u svrhu skrininga. Kontrole su odabrane među osobama po 
prvi put podvrgnutim kolonoskopiji u svrhu skrininga ili ispitivanja nespecifičnih 
abdominalnih tegoba. Na osnovu kolonoskopskih nalaza prikupljeni su podaci o 
eventualnom prisustvu adenomatoznih polipa i karcinoma kolona među slučajevima i 
kontrolama. Hi-kvadrat i Fišerov test su korišćeni kako bi se uporedila distribicija 
kategoričkih varijabli.  
Rezultati: U multicentričnoj bolničkoj studiji devedeset sedam EPM je otkriveno kod 
92 (23.6%) pacijenta sa IPMN. Od toga 78 (80.4%) su bili prethodni, 14 (14.4%) 
sinhroni i 5 (5.2%) metahroni EPM. Utvrđen je značajno povišen O/E odnos za 
prevalentne EPM, i to za kolorektalni karcinom (2.26, CI 95%: 1.17-3.96), karcinom 
bubrega (6.00, CI 95%: 2.74-11.39) i karcinom štitne žlezde (5.56, CI 95%: 1.80-
12.96). Starije doba, pušenje velike količine cigareta, konzumacija alkohola i postojanje 
prvog srodnika sa istorijom karcinoma želuca identifikovani su kao značajni faktori 
rizika za nastanak EPM kod pacijenta sa IPMN, dok je pozitivna porodična anamneza 
za kolorektalni karcinom bila granično značajna. Studija genetske asocijacije nije 
pokazala povezanost IPMN sa SNP rs6983267, rs6993464, rs7014346 i rs10505477. U 
kolonoskopskoj studiji slučajeva i kontrola kolorektalni polipi nađeni su kod 52 (42.6%) 
pacijenta sa IPMN i 79 kontrola (32.1%) (p<0.05). Kod 29 slučajeva (23.8%) i 57 
kontrola (23.2%) histološko ispitivanje utvrdilo je da su u pitanju adenomatozni polipi 
(p=0.90). Nije bilo razlike između slučajeva i kontrola kada je u pitanju bilo prisustvo 
polipa sa diplazijom niskog stepena (19.7% vs. 19.8%, p=0.98), niti visokog stepena 
(4.9% vs. 4.5%, p=0.85).  
Zaključci: Italijanski pacijenti sa IPMN imaju povišenu prevalenciju EPM, naročito 
kolorektalnog karcinoma, karcinoma bubrega i karcinoma štitne žlezde. Stoga bi ovi 
pacijenti trebalo da budu sistemski nadzirani kako bi se navedeni tumori detektovali na 
vreme. Pacijenti sa IPMN nemaju veću prevalenciju SNP rs6983267, rs6993464, 
rs7014346 i rs10505477 u humanom hromozomskom regionu 8q24 u odnosu na opštu 
populaciju. Potrebna su dalja istraživanja kako bi se u ispitalo da li su drugi SNP u 
  
ovom region udruženi sa IPMN. Pacijetni sa IPMN nisu u povišenom riziku od nastanka 
kolorektalnih adenomatoznih polipa.  
 
Ključne reči: pankreas, intraduktalne papilarne mucinozne neoplazme, 
ekstrapankreasni maligniteti, 8q24 region humanog genoma, kolorektalni karcinom, 
kolonoskopija, adenomatozni polipi  
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1. Introduction 
 
1.1 IPMN definition and history 
 
Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas are mucin-
producing epithelial tumors that show a papillary architecture and are associated with 
dilatation of the ducts (1).  This clinical entity was reported for the first time in 1980 by 
Ohhashi et al. (2). They reported a patient with mucin secreting cystadenocarcinoma of 
the pancreas, forming a fistula that drained into the common bile duct. Many similar 
reports followed, giving this clinical entity various names, such as diffuse intraductal 
papillary adenocarcinoma (3), diffuse villous adenoma (4, 5), mucinous pancreatic duct 
ectasia (6), intraductal cystadenocarcinoma (7), intraductal mucin-hypersecreting 
neoplasm (8), mucinous ductal ectasia (9), papillary adenoma (10), intraductal mucin-
producing tumor (11, 12), duct-ectatic type pancreatic ductal carcinoma (13), mucin-
hypersecreting tumor (14), mucous-hypersecreting tumor (15), and intraductal papillary 
neoplasm (16).  Term IPMN was used for the first time by Sessa et al. (17) in 1994. 
This name was further introduced in the classification of exocrine pancreatic tumors 
propagated by the World Health Organization (WHO) (18) and the fascicles of the 
Armed Forces Institute of Pathology (19). 
 
1.2 Histomorphological and clinical characteristics  
 
IPMN is characterized by intraductal papillary proliferation of mucin-producing 
epithelial cells. The tumor usually secretes excessive amounts of mucin. The profuse 
secretion of mucin by IPMN results in cystic dilatation of the pancreatic ducts. 
Therefore IPMNs are included among the cystic tumors of the pancreas (20). Cystic 
tumors of the pancreas include also serous tumors (serous cystadenoma and 
cystadenocarcinoma), other mucinous tumors (mucinous cystic neoplasia), and solid 
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pseudopapillary tumors. However IPMN has certain characteristics that distinguish it 
from the other cystic neoplasm of the pancreas (21). It usually affects individuals 60-70 
years old, and 60-70% among affected are males (22). Tumor is usually localized in 
pancreatic head and always communicates with pancreatic duct determining its diffuse 
or segmental enlargement. Tumor has no capsule and is not characterized with 
calcifications. Except high concentration of mucin, tumor cystic fluid is characterized 
by high concentration of amylase and carcinoembryonic antigen (CEA) (22).   
The epithelial cells of IPMN are characterized by a wide spectrum of dysplasia, ranging 
from mild, intermediate and high-grade dysplasia to invasive carcinoma. Therefore 
IPMNs are precursors of pancreatic carcinomas and provide model of neoplastic 
progression from a benign intraductal tumor through increasing grades of dysplasia to 
invasive adenocarcinoma. Progression from adenoma to carcinoma is estimated to occur 
within about 5–6 years (23, 24). At present, according to international consensus 
guidelines from 2012, only invasive carcinoma derived from IPMN is considered 
malignant, while high-grade dysplasia is not considered malignant (25).   
According to duct involvement IPMNs are classified into main duct IPMNs (MD-
IPMNs) associated with dilation of the main pancreatic duct, branch duct IPMNs (BD-
IPMNs) associated with the dilation of one of the side branches and combined type 
IPMN (C-IPMN) associated with dilation of both main pancreatic duct and at least one 
of the side branches (Figure 1). 
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Figure 1. Morphologic classification of IPMN with schematics (left panels) and radiographic images 
(right panels), including (A and D) MRCP and (B and C) CT. (A) Branch duct IPMN; (B) Diffuse main 
duct IPMN; (C) Segmental main duct IPMN; (D) Mixed IPMN (26)  
Based on the histomorphological features of papillary proliferation and the 
immunohistochemical characteristics of mucin glycoproteins IPMNs are classified into 
intestinal, pancreatobiliary, oncocytic, and gastric types (Figure 2). Intestinal type 
IPMN has villous papillae that express MUC2 and MUC5AC glycoproteins. 
Pancreatobiliary type has an intricate thin arborizing papillary structure that is 
consistently positive for MUC5AC and focally positive for MUC1 but not MUC2. 
Oncocytic type IPMN has complicated thick papillae consisting of eosinophilic 
oncocytic cells that are consistently positive for MUC5AC and focally positive for 
MUC1 and/or MUC2. Gastric type IPMN has finger-like papillary growths that are 
positive for MUC5AC but not for MUC1 or MUC2. The first three types originate from 
the main duct, whereas the gastric type usually originates from the branch ducts. It has 
been reported that histological subtype significantly influences the biological behavior 
and prognosis of IPMN (27-30). While invasive carcinoma derived from the non-
intestinal type IPMN is associated with a poor prognosis (27), invasive carcinoma 
originating from intestinal type IPMN is often minimally invasive (29). 
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Figure 2. Epithelial subtypes of intraductal papillary mucinous neoplasm: (A) gastric; (B) intestinal; (C) 
oncocytic; (D) pancreatobiliary (30). 
 
1.3. Epidemiology  
 
Incidence of IPMN significantly increased in last decades (24, 31, 32). Study from US 
reported a 14-fold increase in the age- and sex-adjusted incidence of IPMN between 
1985 and 2005 (31). IPMN currently accounts for 1%–3% of all exocrine pancreatic 
neoplasms and for 20%–50% of all cystic neoplasms of the pancreas (33-35). 
Furthermore large portion of IPMNs still remains clinically unrecognized, as many of 
them are small and asymptomatic. One imaging study reported presence of small 
asymptomatic IPMN in 2.8% of 2,832 consecutive outpatients examined for conditions 
other than known or suspected pancreatic disease (36). The percentage increased to 
8.7% in individuals aged 80 years and older (36). 
Since the incidence of IPMN increased in the absence of an increase in IPMN-related or 
overall pancreatic cancer-related mortality (31), it is likely that this increase comes from 
 5 
 
improved IPMN diagnosis, rather than greater numbers of patients with clinically 
relevant disease. The diagnosis of IPMN is usually set by endoscopic retrograde 
cholangiopancreatography (ERCP), computed tomography (CT), magnetic resonance 
cholangiopancreatography (MRCP) or endoscopic ultrasound (EUS) (Figures 3 and 4). 
As these imaging methods are becoming more precise and increasingly available, the 
possibilities for accurate IPMN diagnosis multiply. Another explanation could be found 
in increased awareness and better understanding of clinical, radiological, histological, 
and genetic aspects of IPMN. International consensus guidelines for the management of 
IPMN and mucinous cystic neoplasm (MCN) of the pancreas, issued for the first time in 
2006 (37) and revised in 2012 (25) largely contributed to this issue. 
 
Figure 3. EUS showing a mural nodule in the dilated MPD with Doppler flow indicating the presence of a 
blood supply (25). 
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Figure 4. MRCP (left panels) and ERCP (right panels) demonstrating the three morphological types of 
IPMN. A. Main duct type with a mural nodule (arrows). B. Branch duct type.C. Mixed type (25). 
 
1.4 Prognosis 
 
IPMN has better prognosis than pancreatic ductal adenocarcinoma (PDAC), or 
neuroendocrine tumors of pancreas (38). Only the prognosis of patients with advanced 
forms of invasive IPMN is as poor as in those with PDAC (39). However MD-IPMNs 
and C-IPMNs at one side and BD-IPMNs on the other side differ significantly in matter 
of biological behavior. MD-IPMNs have been reported to have worse prognosis than 
BD-IPMNs in most clinical series (40). The explanation lies in greater malignant 
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potential of MD-IPMNs. Malignant tumor is found after resection in 57%–92% of MD-
IPMNs and only 6%–46% of BD-IPMNs (37). The presence of invasive carcinoma was 
reported to be the strongest predictor of survival in IPMN (41-43). Five-year survival 
rates for patients with resected noninvasive IPMNs are 80%– 100% in compare to 40%–
60% in invasive forms (24, 39, 44, 45).  
 
1.5  Clinical presentation and management 
 
Up to 43% of patients with IPMN are reported to be asymptomatic (40). When 
symptoms are present, they usually include nausea and vomiting, weight loss, back pain 
or abdominal pain. Some of IPMN patients may even develop exocrine and endocrine 
pancreatic insufficiency. As these are also the symptoms of chronic pancreatitis, IPMN 
can often be misdiagnosed as chronic pancreatitis. However patients with IPMN present 
different epidemiological characteristics than those with chronic pancreatitis. IPMN 
patients are more often females, are significantly older and are less frequently 
associated with alcohol consumption (46). Nevertheless IPMN patients may actually 
develop chronic pancreatitis due to obstruction of the main pancreatic duct by mucin 
(46). 
Main therapeutic dilemma associated with IPMN is when to submit the patients to 
surgical resection. The therapeutic approach in IPMN patients was systematically 
assessed for the first time in 2006 in Senadai guidelines followed by recommendations 
to resect all MD-IPMNs and C-IPMNs, as well as BD-IPMNs measuring more than 
3cm in diameter (37). However studies which followed after Sendai recommendations 
reported malignancy to be found in only 25% of resected BD-IPMNs, with invasive 
carcinoma in only 17.7% (25). Therefore therapeutic approach was revised in Fukuoka 
guidelines published in 2012, and more conservative approach for treatment of BD-
IPMNs was proposed (25). The Fukuoka guidelines introduced two layers of criteria for 
assessment of IPMN, so called “high-risk stigmata” and “worrisome features”. High 
risk stigmata are considered to be indicative of malignancy and include obstructive 
jaundice, enhanced solid component, and main pancreatic duct size ≥ 10 mm. Patients 
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with these features should undergo resection without delay (25). At the other side, 
worrisome features include clinical acute pancreatisis, a cyst size of ≥ 3 cm, thickened 
and enhanced cyst walls, nonenhanced mural nodules, main pancreatic duct size 5–9 
mm, an abrupt change in the main pancreatic duct caliber with distal pancreatic atrophy, 
and lymphadenopathy (25). Patients with these features should be referred to EUS exam 
for further risk stratification (25). High resolution EUS can help in discrimination 
between benign and malignant IPMN by demonstrating the presence of mural nodules, 
irregularity and thickening of septa between cysts, and the presence of vascularity in 
these structures (47). Furthermore it enables fine-needle aspiration (FNA) of cystic fluid 
for cytological analysis (tumor or atypical cells) and laboratory tests (amylase, CEA).  
The surgical procedures usually conducted for treatment of IPMN include 
pancreaticoduodenectomy and distal pancreatectomy. For non-resected lesions yearly 
follow-up is recommended for lesions with a diameter smaller than 10 mm, 6-12 
months follow-up for lesions of 10–20 mm, and 3-6 months follow-up for lesions of 20–
30mm (37). 
 
1.6 Association of IPMN with extrapancreatic malignancies (EPMs) 
 
It is acknowledged that IPMN patients have an additional risk of developing PDAC 
(48). Uehara et al. reported that 8% of patients with BD-IPMN developed PDAC during 
follow-up (49). However, number of studies reported that patients with IPMN may also 
be at the increased risk of harboring EPMs (Table 1). Since the first report was 
published in 1999 (50), several studies reported that up to 40% of IPMN patients are 
diagnosed with EPMs (51-61) (Table 1). Colorectal cancer (CRC) (50-54, 58, 59, 61), 
gastric cancer (50-54, 58, 59), lung (52, 54, 58), breast (56) and prostate cancers (60) 
are among the most common EPMs diagnosed in IPMN patients. Variety of other 
tumors has also been reported (Table 1). Increasing age (50, 52, 58, 62),  positive family 
history for colorectal cancer (61) and presence of malignant IPMN (58) are reported as 
the main risk factors for EPMs among IPMNs. MUC2 expression was noticed more 
frequently in the IPMN coexisting with EPM than in the IPMN without EPM (63). 
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Some authors also suggested influence of genetic component, as IPMN was reported to 
be associated with familial adenomatous polyposis (FAP) syndrome (64). 
Nevertheless so far available data on association between IPMN and EPM are still 
limited, especially in relation to European population. With exception of one study 
reporting on the occurrence and risk factors of EPMs among IPMNs in French 
population (56), all other studies were conducted in Asia (50-54, 57-59, 62) or in the 
United States of America (USA) (55, 60). The prognosis of IPMNs is generally 
favorable, with a 5-year survival rate around 60-70 % for the non- invasive forms, and 
30-40 % for the invasive forms (23, 24). However, among those who develop EPMs, 
the prognosis is less favorable (50, 52-54). Therefore it is out of exceptional importance 
to investigate whether the patients with IMPN are actually at the increased risk for 
harboring EPMs, so they can be submitted to the increased medical surveillance 
including screening exams for the specific tumors.  
The mechanism(s) causing the potential association between IPMN and EPMs is still 
unknown. It can be hypothesized that common genetic background may be responsible 
for observed association. Human chromosomal region 8q24 has been associated with 
many types of cancer (65-67). The majority of these associations lie at approximately 
128 Mb on chromosome 8. Among them one prominently associated SNP, rs6983267, 
has been shown to interact with the myelocytomatosis viral oncogene homolog gene 
(MYC) (68). The region contains several other genes which could be functionally 
related to cancer development, including nephroblastoma over-expressed gene (NOV), 
which encodes a regulatory protein from the CCN family that has been associated with 
cancer development (69). Furthermore, as several studies suggest the possibility that 
some loci in 8q24 influence more than one type of cancer per locus (70) it could be a 
case that this region contain loci that affect general cancer susceptibility. Knowing this 
it can be hypothesized that presence of single-nucleotide polymorphisms (SNPs) in 
8q24 region could be responsible for increased propensity of IPMN patients to develop 
EPMs. 
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1.7 IPMN and CRC 
 
The most frequent EPM consistently found in these patients has been CRC (50-54, 58, 
59, 61) (Table 1). Up to 11.9% of patients with IPMN are reported to also harbor CRC 
(50). CRC represents the third most common cancer worldwide with more than 1.3 
million new cases (9.7% of total) and almost 700.000 deaths every year (71). Almost 
55% of the cases occur in more developed regions (71), where the prognosis is 
relatively favourable with 5-year survival rate reaching 65% in USA, Canada, Australia 
and several European countries (72, 73). However, incidence is increasing in countries 
or areas with poor health-care resources (74), where 5-year survival is no more than 
50% (75). Therefore the identification of all risk factors associated with CRC becomes 
of paramount importance to apply properly designed screening programs to those at 
higher risk than the general population in order to detect precancerous lesions or cancers 
at an early and more curable stage. 
It is well known that almost all sporadic CRCs develop slowly over several years 
through the adenoma-carcinoma carcinogenetic sequence (76). Thus, it is possible to 
hypothesize that the increased risk of CRC in IPMN patients may be related to an 
increased propensity to develop colorectal adenomas, which represent the precursors of 
sporadic CRC. Some authors have previously reported an increased prevalence of 
colorectal polyps in patients with IPMN, based on which they proposed to consider 
screening colonoscopy for all patients with IPMN (60). This inference, however, has 
been based only on the result of this single study that was retrospective and based on 
chart review, while no data coming from studies specifically designed to prospectively 
assess the rate of colonic polyps in IPMN patients are available. 
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Table 1. Characteristics of studies conducted on association between intraductal papillary mucinous neoplasms (IPMN)s and extra-pancreatic 
malignancies (EPM)s and their findings in relation to EPM occurrence in general as well as in relation to specific malignancies 
Author Study design Year  Country No EPM        
occurrence 
CRC* Gastric    
cancer 
Lung      
cancer 
Breast    
cancer 
Prostate    
cancer 
EPM risk       
factors 
Sugiyama et al (50).  Retrospective 1999 Japan 42 35.7% 11.9% 9.5% 2.4% 2.4% 2.4% age (p<0.05) 
Osanai et al. (51) Retrospective 2003 Japan 148 23.6% 7.4% 5.4% 3.4% 0% 1.4% NRˠ 
Kamisawa et al. (52) Retrospective 2005 Japan 79 35.4% 8.9% 15.2% 5.1% 2.5% 1.3% age (p<0.05) 
Choi et al. (53) Retrospective 2006 South 
Korea 
61 29.5% 6.6% 13.1% 0% 0% 0% none 
Eguchi et al. (54) Retrospective 2006 Japan 69 38% 11.6% 5.8% 7.2% 0% 2.9% age (for CRC) 
Riall et al. (55) Population-based 2007 USA 992 10.1% 2.5% 0.1% 0.8% 1.8% 1.4% NR 
Baumgaertner et al. 
(56) 
Case-control 2008 France 178 16.8% 1.7% NR 1.7% 5.4% 2.2% none 
Ishida et al. (57) Retrospective 2008 Japan 61 24.6% 8% 10% NR NR NR none 
Yoon et al. (58) Retrospective 2008 South 
Korea 
210 33.8% 7.6% 13.8% 1.4% 0% 0.5% age                     
invasive IPMN 
Oh et al. (59) Retrospective 2009 South 
Korea 
37 27% 8.1% 8.1% 5.4% 0% 2.7 NR 
Reid-Lombardo et al. 
(60) 
Retrospective 2010 USA 471 40.8% 4.0% 0% 0.6% 5.1% 5.0% NR 
Lubezky et al. (61)  Retrospective 2011 Israel 82 19.5% 6.1% 0% 1.2% 3.7% 3.7% CRC 1st-degree     
family history 
Kawakubo et al. (62) Prospective 2011 Japan 642 6.0% 0.9% 0.9% 0.8% 0% 0.6%  NR 
*CRC=colorectal cancer 
         ˠNR=not reported 
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2. Objectives 
 
In the light of previously mentioned facts, three separate studies were designed in order 
to address potential association between IPMN and EPMs. The work hypotheses were 
defined as follows: 
 Extrapancreatic malignancies (EPMs) occur significantly more frequent in 
patients with IPMNs of the pancreas in compare to the general population. 
 IPMNs are associated with SNPs in 8q24 region of human genome. 
 Patients with IPMN harbour significantly more colorectal adenomas than IPMN 
free controls. 
In concordance with named hypotheses following objectives were defined:  
 The primary objective of the thesis is to assess the prevalence and incidence of 
EPMs in a cohort of Italian patients diagnosed with IMPN, and to identify the 
risk factors for their occurrence.  
 The secondary objective is to assess an association between IPMN and selected 
SNPs within 8q24 region of human genome. 
 The tertiary objective of the thesis is to assess whether patients with IPMNs 
have an increased propensity to develop colorectal adenomas. 
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3. Methods 
 
In order to meet the objectives three separate studies were conducted: the hospital-based 
multicentric study, the genetic-association study and colonoscopic case-control study. 
 
3.1. The hospital-based multicentric study 
 
The hospital-based multicentre study was conducted to assess the prevalence and 
incidence of EPMs in a cohort of Italian patients diagnosed with IMPN, and to identify 
the risk factors for their occurrence. 
 
3.1.1 Study Design 
 
The study was conducted at the participating centres upon Hospital Review Boards 
approval (77). Participating centres in Italy were: Digestive Endoscopy Unit, Università 
Cattolica del Sacro Cuore, and Digestive and Liver Disease Unit, “Sapienza” 
University, Rome; Surgery, University of Verona, and Gastroenterology, University of 
Verona, Verona; Gastroenterology & Gastrointestinal Endoscopy, San Raffaele 
Hospital, and Surgery Istituto Humanitas, Milano, Italy;  Surgery, University of Pisa, 
Pisa; Gastroenterology, S. Agostino Hospital, Modena; Gastroenterology, Bellaria 
Maggiore Hospital, and Internal Medicine, University of Bologna, Bologna; Endoscopy, 
Ismet, Palermo (Figure 5). 
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Figure 5. Map of Italy with all the participating centres marked. 
 
Prevalent cases of patients with either a new diagnosis of IPMN or those seen during 
follow-up at the participating units during an 18-months period (January 2010 to June 
2011) were enrolled. Inclusion criteria were: a) age > 18 years old; b) will and ability to 
cooperate. The criteria for the identification of IPMN cases are previously described 
(78). Patients were excluded if they have cystic lesions other than IPMN. The type of 
duct involvement was determined at each participating unit by revision of clinical 
imaging studies and of macroscopic and microscopic examinations when available, and 
classified as MD-IPMNs, BD-IPMNs or C-IPMNs.  
EPMs were defined as secondary primary tumour occurring in IPMN patients, with a 
histological confirmation. EPMs were grouped according to the time of their diagnosis: 
1) previous EPMs, which were diagnosed before the IPMN diagnosis; 2) synchronous 
EPMs, diagnosed at the same time of IPMN; 3) metachronous EPMs, diagnosed during 
the follow-up of IPMN patients. We considered previous and synchronous as prevalent 
EPMs, while metachronous as incident EPMs. IPMN cases were followed-up for an 
average period of 13 months (5-31 months). The follow-up for each individual patient 
was scheduled according with published guidelines (37), and included abdominal 
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ultrasound, CT, magnetic resonance imaging or EUS. Additional investigations, such as 
gastroscopy, colonoscopy or chest x-ray were performed when judged to be clinically 
indicated, while no standard screening procedures were performed. 
 
3.1.2 Data collection 
 
IPMN patients were interviewed by a trained physician who filled-in a structured 
questionnaire to collect data on demographics, medical and family history and lifestyle 
habits. To avoid possible bias due to cancer symptoms or subsequent cancer therapies 
(either surgical or medical), subjects were asked about lifestyle habits referred to the 12 
months before the IPMN diagnosis or presentation of IPMN symptoms. The following 
data were recorded: age, gender, weight, height, (Body mass Index (BMI) was 
subsequently calculated), family history of cancers (1st and 2nd degree), clinical history 
(history of pancreatitis, diabetes, peptic ulcer and cholecystectomy; use of certain 
drugs), and lifestyle habits (cigarette smoking status and alcohol drinking assumption). 
Ever cigarette smokers were defined as those who ever smoked cigarettes for at least 6 
months or smoked at least 100 cigarettes during the lifetime. The amount of cigarette 
smoking was evaluated as pack-years (number of packs per day X years of smoking). 
Ever alcohol drinkers were defined as those drinking at least 12.5 g of alcohol (one 
glass of wine, or one pint/can of beer, or one shot of hard liquor) per day for at least one 
year. We defined “recent onset diabetes” as diagnosed during the 12 months before the 
diagnosis of IPMN.  
 
3.1.3 Statistical analysis 
 
For previous and synchronous EPMs (prevalent EPMs), the ratio of the observed (O) 
number of patients with EPMs to the expected (E) number was calculated along with 
95% confidence interval (CI) (79). We excluded in this calculation the metachronous 
tumours (incident EPMs) in view of the short follow-up. Data on age-stratified and 
gender-specific prevalence of cancer in Italy were used to determine the expected 
number of EPMs (80). We compared the distribution of the demographics, medical and 
family history, lifestyle habits variables among patients with and without EPMs by 
univariate analysis. Chi-square and Fisher's exact tests were used where appropriate. 
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Statistical analyses were performed using Stata 11.2 (Stata Corporation, College 
Station, TX).3.2. 
 
3.2 The genetic-association study 
 
Genetic-association study was conducted in order to assess an association between 
pancreatic IPMN and selected SNPs within 8q24 region of human genome. 
 
3.2.1. Study design 
 
The study was conducted at the Digestive Endoscopy Unit of the Catholic University 
Rome, Italy.  Prevalent cases of patients with either a new diagnosis of IPMN or those 
seen during follow-up at the participating units during an 18-month period (January, 
2010 to June, 2011) were enrolled. The criteria for the IPMN diagnosis have been 
previously described (78). The diagnosis of IPMN was considered as certain in the 
presence of either histological diagnosis obtained by EUS or surgical specimen, or 
cytologic diagnosis obtained by EUS. A highly probable diagnosis of IPMN was based 
on the presence of one or several main pancreatic duct and/or branch duct dilatation(s) 
and/or pancreatic cystic lesions communicating with pancreatic ducts at CT, magnetic 
resonance cholangiopancreatography with secretin stimulation (S-MRCP), ERCP or 
EUS. Patients were excluded if they had cystic lesions other than IPMN. The controls 
included patients from the same hospital with a broad range of diagnoses, enrolled 
during the same time period. Around 50% of the controls were outpatients, and the 
remaining were patients undergoing surgical interventions (laparoscopic 
cholecystectomy, appendicitis, inguinal hernia) or admitted for a wide spectrum of other 
non neoplastic diseases. Controls were matched to each IPMN case by gender and age 
(±5 years). Written informed consent was obtained from all study subjects. The study 
was conducted according to the Declaration of Helsinki and was approved by the 
Ethical Committee of Università Cattolica del Sacro Cuore. Both cases and controls 
were interviewed by trained physicians using a structured questionnaire and data on 
demographics, lifestyle habits (alcohol consumption, cigarette smoking), prior medical 
history, cancer family history and medication use were collected. 
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3.2.2 SNPs genotyping 
 
SNPs rs10505477, rs6983267, rs7014346 and rs6993464 within 8q24 region of human 
genome have been selected to be tested in the study. Among all the SNPs within 8q24 
region, these have been most frequently reported to be significantly associated with 
cancer susceptibility in general. 
Genomic DNA from whole blood samples was extracted by using salting out protocol. 
This method uses lysis buffer that contains detergent and salts and creates a hypertonic 
condition resulting in lysis of cells. The DNA concentration was measured by the 
spectrophotometer. The working solutions were obtained at a final concentration of 10 
ng /l and stored at -20 °C. All SNPs were performed using a StepOne Real-time PCR 
system (Applied Biosystems) and commercial kits TaqMan SNP Genotyping Assay™ 
40X (Assay IDs: C__29809139_20, C__29086771_20, C__29086780_10, 
C___2149241_10, Applied Biosystems). PCR reactions were done according to the 
manufacturer's protocol with a final volume of reaction 15 l per well. The program 
used considered an initial step of 10 minutes at 95 ° C, followed by 40 cycles at 95 ° C 
of 15 seconds each, and one minute at 60 ° C. Allelic Discrimination was determined by 
the Step One software applying the fluorescence probes. The Fluorescence values were 
detected in the FAM channel for the allele 1 and VIC channel for the allele 2. The dye 
used as the passive reference was ROX. 
 
3.2.3 Statistical analysis 
 
Hardy-Weinberg equilibrium (HWE) was tested for the control SNPs. Descriptive 
analysis using proportion and means ± standard deviation was computed for categorical 
and quantitative variables. Differences between groups were calculated using chi-
squared and two-sample t-tests. 
Association of IPMN with named SNPs was assessed by fitting unconditional multiple 
logistic regression models both to investigate departure from the multiplicative model 
and to identify the effect model best fitting the data. We started by modelling the 
relationship between IPMN and the genetic markers to try to underpin the transmission 
inheritance model. We fitted the regression model at a genotype level by assuming the 
following genetic models: not assuming any model, a dominant, a recessive and 
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multiplicative. A Likelihood Ratio Test was used to check the departure from a 
multiplicative model. Finally, ORs of IPMN and corresponding 95% CI according to 
analysed polymorphisms were derived from unconditional multiple logistic regression 
models using the multiplicative model, including terms for age and sex.  
We also examined the possible confounding effect of smoking, alcohol, and cancer 
family history. However, models including these covariates yielded very similar results. 
Thus, given the small numbers in some strata, only the age- and sex-adjusted estimates 
were presented. Finally, Results were stratified according to any cancer 1st-degree 
family history. 
 
3.3. The colonoscopic case-control study 
 
Colonoscopic case-control study was conducted in order to assess whether patients with 
pancreatic IPMN have an increased propensity to develop colorectal adenomas. 
 
3.3.1 Study design 
 
A two centre prospective case-control study was conducted at the Digestive Endoscopy 
Unit of the Catholic University and the Digestive and Liver Disease Unit of the 
University Sapienza, Rome, Italy between January 2012 and December 2013. Cases 
were prevalent IPMN who underwent screening colonoscopy for the first time in their 
life. The criteria for the IPMN diagnosis have been previously described (78). The 
diagnosis of IPMN was considered as certain in the presence of either histological 
diagnosis obtained by EUS or surgical specimen, or cytologic diagnosis obtained by 
EUS. A highly probable diagnosis of IPMN was based on the presence of one or several 
main pancreatic duct and/or branch duct dilatation(s) and/or pancreatic cystic lesions 
communicating with pancreatic ducts at CT, S-MRCP, ERCP or EUS. Patients were 
excluded if they had a history of CRC, if they had undergone a previous colonoscopy 
independently on the presence or absence of CRC and/or colonic polyps, and if they had 
cystic lesions other than IPMN. Controls matched to each IPMN case (2:1) by gender 
and age (±5 years) were enrolled alongside among individuals who underwent their first 
colonoscopy for screening or for evaluation of non-specific abdominal symptoms at 
both institutions. Individuals who underwent colonoscopy because of a personal history 
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of CRC, of FAP or hereditary non-polyposis colorectal cancer (HNPCC), positivity to 
fecal occult blood test, iron deficiency anaemia and bright red blood per rectum were 
excluded. Both cases and controls were interviewed by trained physicians using a 
structured questionnaire and data on demographics, lifestyle habits (alcohol 
consumption, cigarette smoking), prior medical history and cancer family history were 
collected. 
For IPMN cases data on IPMN characteristics, such as type of ductal involvement, 
focality, maximal dilation of the duct and presence of nodules or solid tissue inside the 
cyst cavity were collected. The type of duct involvement was determined by revision of 
clinical imaging studies and/or based on EUS evaluation, and classified as MD-IPMNs, 
BD-IPMNs or C-IPMNs. 
 
3.3.2 Colonoscopies 
 
Cases and controls underwent screening colonoscopy and the prevalence of colon 
polyps and/or colorectal cancer was determined. Polyethylene glycol lavage solution 
was used for colon preparation. Colonoscopies were conducted by experience 
endoscopists at the Digestive Endoscopy Unit of the Catholic University and the 
Digestive and Liver Disease Unit of the University Sapienza. Anatomical landmarks 
(Bauchini valve and appendix orifice) were recognized as proof that entire colon has 
been examined. Patients who were diagnosed with CRC were referred to surgical 
evaluation, while all detected polyps were removed when possible. Histopathologic 
examination of all removed polyps was performed and histologic type of the polyp and 
the degree of dysplasia were determined. All colonoscopies were performed under 
conscious sedation (midazolam and phentanyl e.v.) and patients were observed in 
recovery unit for 1 hour after the procedure. For those with positive colonoscopy 
findings, surveillance was suggested after proper treatment and histopathologic 
evaluation, according to current guidelines (81). 
 
3.3.3 Statistical analysis 
 
We conducted a descriptive analysis using relative frequencies and percentages to 
summarize the characteristics of the IPMN patients at the time of diagnosis. Chi-square 
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and Fisher exact tests were used to compare the distribution of categorical variables 
between patients with IPMNs and control subjects. Additionally, as we expect that the 
prevalence of colorectal polyps might differ between the compared groups based on the 
family history of CRC, we have planned a priori to stratify our data according to 1st-
degree family history of CRC. Statistical analyses were performed using Stata software 
(StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp 
LP). 
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4. Results 
 
4.1. The hospital-based multicentric study 
 
Demographic of 390 IPMN patients included in the study are reported in Table 2.  
 
 
Table 2. Demographics of 390 patients with 
intraductal papillary mucinous neoplasms (IPMN)s 
at the time of diagnosis 
 
  
IPMNs 
(N=390) 
    
Male 166 42.6% 
Female 224 57.4% 
 
Age (years)   
 <50 36 9.2% 
 50-59 68 17.4% 
 60-69 139 35.6% 
 70-79 118 30.3% 
 >80 29 7.4% 
 
Body-mass index (kg/m2) 25 23-27 
 
Data are median (IQR) for continuous variables or number of individuals (%) for 
discrete variables 
(§) The percentage of missing value >5% 
     
 
 
IPMN cases were predominantly female (57.4%). Most of the cases were of age 60-69 
(35.6%) and 70-79 (30.3%), while 17.4%, 9.2% and 7.4% were of age 50-59, <50 and 
>80 respectively.  Median body-max index of the patients included was 25 kg/m2 (Table 
2). 
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Table 3 reports the clinical characteristics of 390 IPMN patients included in the study. 
Three hundred and ten patients (79.5%) had BD-IPMN, 20 (5.1%) were diagnosed MD-
IPMN, while 60 (15.4%) were having both branch and main duct involvement.  
 
 
Table 3. Clinical features of 390 patients with 
intraductal papillary mucinous neoplasms (IPMN)s 
at the time of diagnosis 
 
  
IPMNs 
(N=390) 
    
Duct Involvement   
 IPMN-BD 310 79.5% 
 IPMN-MD 20 5.1% 
 IPMN-mixed 60 15.4% 
 
Focality   
 Unifocal 142 36.5% 
 Multifocal 247 63.5% 
 
Treatment   
 Surgery 63 16.2% 
  No surgery 327 83.8% 
 
Data are median (IQR) for continuous variables or number of individuals (%) for 
discrete variables 
(§) The percentage of missing value >5% 
     
 
 
Two hundred forty seven patients (63.5%) were diagnosed with more than one IPMN, 
while in 142 (36.5%) patients IPMN was unifocal. Only small portion of patients 
included (16.2%) underwent surgery in order to treat IPMN (Table 3). 
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The second primary malignancy was observed in 92 (23.6%) patients with IPMN; 
precisely 97 EPMs were diagnosed in 92 patients (Figure 6).  
 
 
 
 
Seventy eight EPMs (80.4%) were previously diagnosed in 74 patients, 14 EPMs 
(14.4%) were diagnosed synchronous in 14 patients, and 5 (5.2%) were diagnosed 
metachronous in 4 patients (Figure 7).  
 
 
Patients without 
EPMs 
76.4% 
Patients with 
EPMs 
23.6% 
Figure 6. Occurrence of extrapancreatic malignancies 
(EPM)s among IPMN patients included in study 
Previous EPMs 
80% 
Synchronous 
EPMs 
15% 
Metachronous 
EPMs 
5% 
Figure 7. Distribution of  extrapancreatic malignancies 
(EPM)s according to time of diagnosis 
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The most common tumors were breast cancer (15 cases, 15.5%), CRC (12 cases, 
12.4%), renal cell carcinoma (9 cases, 9.3%), prostate carcinoma (8 cases, 8.2%), 
hematological cancers (7 cases, 7.2%) and thyroid carcinomas (5 cases, 5.2%) (Table 
4).  
 
Table 4. Extrapancreatic malignancies (EPMs) in patients with intraductal 
papillary mucinous neoplasms (IPMNs) 
    Previous Synchronous Metachronous Total 
      
 Breast (*) 12 3 0 15 
 Colorectal 7 5 0 12 
 Renal cell 8 1 0 9 
 Prostate 7 0 1 8 
 Hematological 6 0 1 7 
 Thyroid 5 0 0 5 
 Bladder 4 0 0 4 
 Hepatocellular 2 2 0 4 
 Lung 3 0 1 4 
 Melanoma 4 0 0 4 
 Non- melanoma skin 2 1 0 3 
 Ovary 3 0 0 3 
 Uterus 3 0 0 3 
 Gastrointestinal stromal 2 0 0 2 
 Meningiomas 2 0 0 2 
 Neuroendocrine gastrointestinal 1 0 1 2 
 Neuroendocrine lung 2 0 0 2 
 Acoustic neuroma 0 0 1 1 
 Ampullary intestinal-type 0 1 0 1 
 Gastric 1 0 0 1 
 Oesophageal 0 1 0 1 
 Oropharyngeal 1 0 0 1 
 Parotid adenocarcinoma 1 0 0 1 
 Thymoma 1 0 0 1 
 Ureter 1 0 0 1 
      
  Total 78 14 5 97 
      
(*) Includes 1 male with breast cancer.     
NOTE: Patients with EPMs are 92. Five patients have two cancers: breast + ovary, 
prostate + renal, prostate + hematological, uterus + breast, uterus + ovary. 
 
Four cases of PDACs (1 previous and 3 synchronous) and 3 pancreatic neuroendocrine 
tumors (all of them synchronous) were also diagnosed. 
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The O/E ratios for previous and synchronous EPMs are reported in Table 5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A significantly increased occurrence of CRC (2.26, 95% CI: 1.17-3.96), renal cell 
carcinoma (5.33, 95% CI: 2.30-10.51) and thyroid carcinoma (5.66, 95% CI: 1.80-
12.96) was observed in IPMN cases in comparison with Italian general population, 
while significance for hematological cancers (3.00, 95% CI: 0.96-5.68) was borderline 
(Table 5).  
An increased risk for PDAC was also identified among IPMN patients (O/E=20, 95% 
CI: 5.41-51.21).  
  
 
Table 5. Observed and expected number of extra-pancreatic 
malignancies (EPMs) in 390 patients with intraductal papillary 
mucinous neoplasms (IPMNs) 
 
  Observed Expected O/E ratioˠ CI 95% 
      
 Breast* 14 8.0 1.75 0.88-2.70 
 Colorectal 12 5.3 2.26 1.17-3.96 
 Renal cell 9 1.5 6.00 2.74-11.39 
 Prostate 7 4.0 1.75 0.64-3.28 
 Hematological 6 2.0 3.00 0.96-5.68 
  Thyroid 5 0.9 5.56 1.80-12.96 
 
ˠO/E ratio=observed/expected ratio 
*Calculated for females (1 male with breast cancer excluded) 
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When comparing IPMN patients with and without EPMs according to demographics 
and lifestyle habits (Table 6), increasing age (p<0.05) and ever alcohol consumption 
(p<0.05) were observed as significant risk factors for EPM. 
 
 
.  
Although we did not observe that EPMs are significantly more common in ever smokers 
in compare to never smokers, those consuming ≥20 pack-years were significantly more 
represented among patients with EPMs (p<0.05) (Table 6). 
Table 6. Demographics and lifestyle habits of 390 intraductal papillary mucinous 
neoplasm (IPMN) cases with and without extrapancreatic malignancies (EPMs)  
  
Without EPMs 
(N=298) 
With EPMs 
(N=92) p value 
Demographics 
Male Sex 
 
127 (42.6%) 
 
39 (42.4%) 
 
0.97 
Age 64.4 ±11.4 67.9 ±9.3 <0.05 
BMIˠ 25.1 ±3.9 25.1 ±3.9 0.88 
Cigarette smoking       
Ever 153 (51.7%) 45 (51.1%) 0.9 
<20 pack-years 
≥20 pack-years 
54 (45 %) 
66 (55%) 
9 (25%) 
27 (75%) <0.05 
Alcohol    
Ever 101 (34.5%) 41 (46.6%) <0.05 
≤20 units per week 
>21 units per week 
60 (78.9%) 
16 (21.1%) 
23 (79.3%) 
6 (20.7%) 0.36 
ˠ BMI = Body-mass index (kg/m2)    
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When comparing IPMN patients with and without EPMs according to medical history 
and cancer family history (Table 7), 1st degree family history of PDAC (p<0.01), 
medical history of peptic ulcer (p<0.05) and 1st degree family history of gastric cancer 
(p<0.05) were observed to act protectively on the occurrence of EPMs.  
 
Table 7. Characteristics of 390 intraductal papillary mucinous neoplasm (IPMN) cases 
with and without extrapancreatic malignancies (EPMs) by selected covariates. 
  
Without EPMs 
(N=298) 
With EPMs 
(N=92) p value 
Clinical history    
History of chronic pancreatitis 10 (3.4%) 2 (2.2%) 0.74 
History of diabetes 40 (13.4%) 13 (14.3%) 0.83 
Recent-onset diabetes 4 (1.3%) 1 (1.1%) 1.00 
History of peptic ulcer 26 (8.7%) 2 (2.2%) <0.01 
History of cholecystectomy 42 (14.5%) 10 (11.0%) 0.40 
Cancer family history    
Any cancer (1st degree) 131 (44.3%) 50 (54.3%) 0.09 
Any cancer (2nd degree) 46 (15.5%) 10 (10.9%) 0.27 
PDAC* (1st degree) 21 (7.1%) 0 (0.0%) <0.005 
PDAC (2nd degree) 8 (2.7%) 5 (5.4%) 0.20 
IPMN (1st degree) 2 (0.7%) 2 (2.2%) 0.23 
Cancer sites (1st degree)     
Colorectal cancer  27 (9.1%) 15 (16.3%) 0.05 
Gastric cancer  12 (4.0%) 9 (9.8%) <0.05 
Breast cancer 16 (5.4%) 6 (6.5%) 0.68 
Lung cancer 21 (7.1%) 6 (6.5%) 0.86 
Uterine cancer 9 (3.0%) 5 (5.4%) 0.33 
Melanoma 3 (1.0%) 0 (0.0%) 1.00 
Hepatocellular carcinoma 12 (4.0%) 3 (3.3%) 1.00 
Drugs    
Use of aspirin 39 (13.1%) 10 (11.1%) 0.62 
Use of statins 36 (12.1%) 11 (12.2%) 0.97 
Use of insulin 13 (4.4%)  6 (6.6%) 0.41 
*PDAC = pancreatic ductal adenocarcinoma 
 
First degree family history of CRC was borderline significant risk factor for EPM 
(p=0.05) (Table 7). The occurrence of EPMs was more frequent among non-surgical 
IPMN patients (p<0.005) 
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4.2. The genetic-association study 
 
The demographics of 117 IPMN cases and 231 controls included in the study are 
reported in Table 8.  
 
 
 
Table 8. Demographics of 117 intraductal papillary mucinous neoplasm (IPMN) 
cases  and 231 controls  
 
  IPMN cases    Controls                
  N (%)   N (%)   
Age (years) 63.5 ± 11.8*   63.8 ± 12.5* p=0.81 
Gender           
 
   Male 70 (59.8)   135 (58.4) p=0.80 
   Female 47 (40.2)   96 (41.6) 
 
*mean±standard deviation (SD)           
 
 
 
Cases were of mean age 63.5 ± 11.8, while controls were 63.8 ± 12.5 years old.  Among 
cases 59.8% were males in compare to 58.4% in controls.   
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The cancer family history and lifestyle habits of 117 IPMN cases and 231 controls 
included in genetic association study are reported in Table 9.  
 
 
Cases were more likely to report any cancer 1st degree family history than controls 
(p<0.001). Among cases was significantly more heavy smokers (p=0.001) and heavy 
drinkers (p<0.001) (Table 9).  
 
 
 
 
 
 
Table 9. Distribution of 117 intraductal papillary mucinous neoplasm (IPMN) 
cases  and 231 controls according to lifestyle habits  and cancer family history 
 
  IPMN cases    Controls                
  N (%)   N (%)   
Age (years) 63.5 ± 11.8*   63.8 ± 12.5* p=0.81 
Gender           
 
   Male 70 (59.8)   135 (58.4) p=0.80 
   Female 47 (40.2)   96 (41.6) 
Any cancer 1st degree family 
historya 
71 (62.3)   65 (30.1) p<0.001 
CRCˠ 1st degree family historya 15 (13.2)   16 (7.5) p=0.10 
Smokinga           
 
   Never 47 (41.0)   138 (59.7) 
p=0.001    Ex-smoker 15 (12.9)   32 (13.9) 
   Current-smoker 8 (6.9)   15 (6.5) 
   >20 pack/years 46 (39.3)   46 (20.0) 
Alcohol gr/day           
 
   < 12 gr/day 51 (43.6)   147 (63.6) 
p<0.001 
   12-23 gr/day 13 (11.1)   47 (20.4) 
   > 23 gr/day 53 (45.3)   37 (16.2) 
ˠCRC=colorectal cancer 
aThe sum does not add up to the total because of missing values. 
*mean±standard deviation (SD)           
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Table 10 reports the distribution of cases and controls, ORs and 95% CIs for IPMN 
according to the selected SNPs (Table 10).  
 
 
Table 10. Distribution of cases and controls, according to studied single-nucleotide 
polymorphisms (SNP)s and their association with intraductal papillary mucinous 
neoplasms (IPMN)s 
 
 IPMN cases (N=117) Controls (N=231) 
p-valuea OR*(95% CI)ˠ 
 N % N % 
rs10505477     0.29  
wtⁱ/wt 26 23.01 60 30.45  1 
wt/mt† 61 53.98 113 51.36  1.30 (0.93-1.82) 
mt/mt 26 23.01 40 18.18  1.69 (0.86-3.31) 
rs6983267     0.28  
wt/wt 21 18.58 57 25.91  1 
wt/mt 68 60.18 115 52.27  1.16 (0.82-1.62) 
mt/mt 24 21.24 48 21.82  1.35 (0.67-2.62) 
rs7014346     0.57  
wt/wt 37 32.74 85 38.46  1 
wt/mt 61 53.98 111 50.23  1.20 (0.85-1.70) 
mt/mt 15 13.27 25 11.31  1.44 (0.72-2.89) 
rs6993464     0.57  
wt/wt 30 26.55 71 32.13  1 
wt/mt 61 53.98 111 50.23  1.09 (0.88-1.37) 
mt/mt 22 19.47 39 17.65  1.19 (0.77-1.88) 
ap-value of the chi square test 
*OR=odds ratio; ˠ95% CI=95% confidence interval.  
ⁱwt=wild-type allele. 
†mt=variant-type allele 
 
No significant association was observed between the selected SNPs and IPMN (Table 
10). 
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4.3. The colonoscopic case-control study 
 
One hundred and twenty-two patients with IPMN and 244 matched controls were 
prospectively enrolled in the study. Table 11 reports demographic characteristics of the 
cases included in the study. 
 
 
Table 11. Demographics of the 122 patients with intraductal 
papillary mucinous neoplasms (IPMN)s of the pancreas at the 
time of diagnosis 
 
 
Number % 
Gender 
  
    Male 47 38.5% 
    Female 75 61.5% 
Age 
  
    <50 15 12.3% 
    50-59 22 18.0% 
    60-69 43 35.2% 
    ≥70 42 34.4% 
 
 
 
IPMN were predominantly female (61.5%), with an age greater than 60 years in 69.6% 
of the cases (Table 11). 
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Table 12 reports the clinical features of the IPMN cases included in the study (Table 12) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The large majority of the cases were BD-IPMN (87.7%) multifocal (67.2%) and without 
evidence of intra-lesional nodules (81.1%). The mean diameter of the largest lesions 
was 16.7±7.9mm, while the mean dilatation of the main pancreatic duct in MD-IPMN 
was 9.0±5.26mm (Table 8). EUS±FNA was performed in 80% of the IPMNs and 
overall they were treated conservatively with clinical follow up in 86.9% of the cases 
(Table 12). 
 
Table 12. Clinical features of the 122 patients with intraductal 
papillary mucinous neoplasms (IPMN)s of the pancreas at the 
time of diagnosis 
 
 
Number % 
Duct Involvement 
  
    BD-IPMN* 107 87.7% 
    MD-IPMNⁱ 7 5.7% 
    C-IPMNˠ 8 6.6% 
Focality 
  
    Unifocal 40 32.8% 
    Multifocal 82 67.2% 
Branch duct maximum dilatation (mm)§ 16.69 12.0-21.0 
Wirsung maximal dilatation (mm)§ 9.0 5.0-10 
Nodules 
  
    No 99 81.1% 
    Yes 23 18.9% 
Surgery 
  
    No 106 86.9% 
    Yes 16 13.1% 
Endosonography 
  
    No 27 22.1% 
    Yes 95 77.9% 
*BD-IPMN=branch duct 
ⁱMD-IPMN=main duct 
ˠC-IPMN=combined 
§Median and interquartile range 
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Table 13 reports demographics and lifestyle habits of IPMN cases and controls (Table 
13).  
 
 
Table 13. Demographics and lifestyle habits of 122 cases with intraductal papillary mucinous 
neoplasms (IPMN)s of the pancreas and  246 controls included in study 
  
  
Cases 
(n=122)   
Controls 
(n=246)   
p 
value 
         
 
Male sex 47 38.5% 
 
94 38.2% 
 
0.95 
 
Age 63.4 ±11.3 
 
62.3 ±10.9 
 
0.25 
Cigarette smoking  
       
 
Ever 64 53.8% 
 
115 46.7% 
 
0.21 
 
≥20 pack-years 33 28.2% 
 
48 19.5% 
 
0.06 
Alcohol  
       
 
Ever 53 44.5% 
 
75 30.5% 
 
<0.01 
 
≥21 drinks per week 10 9.0% 
 
7 2.9% 
 
<0.05 
         
Data are mean (SD) for continuous variables or number of individuals (%) for discrete 
variables   
 
 
 
 
Cases were of mean age 63.4 ± 11.3, while controls were 62.3 ± 12.9 years old.  Among 
cases 38.5% were males in compare to 38.2% in controls. There was no difference in 
age and gender structure of cases and controls. Cases were significantly more likely to 
be ever drinkers (p<0.01) or to drink ≥21 drinks per week (p<0.05) (Table 13).  
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Table 14 reports previous medical history and cancer family history of IPMN cases and 
controls (Table 14).  
 
 
Table 14. Characteristics of 122 patients with intraductal papillary mucinous neoplasms (IPMN)s 
of the pancreas and 246 controls by selected variables of medical history and cancer family 
history 
 
  
Cases 
(n=122)   
Controls 
(n=246)   
p 
value 
Medical history 
       
 
History of chronic pancreatitis 8 6.7% 
 
0 0.0% 
 
<0.001 
 
History of diabetes 23 19.3% 
 
18 7.3% 
 
<0.001 
 
  History of insulin-dependent diabetes 6 5.0% 
 
0 0.0% 
 
<0.001 
 
  History of noninsulin-dependent diabetes 17 14.3% 
 
16 6.7% 
 
<0.05 
 
History of peptic ulcer 4 3.3% 
 
3 1.2% 
 
0.23 
 
History of cholecystectomy 20 16.7% 
 
17 6.9% 
 
<0.01 
Cancer family history 
       
 
Any cancer (1st degree) 70 57.9% 
 
134 57.8% 
 
0.99 
 
Any cancer (2nd degree) 22 18.2% 
 
24 10.3% 
 
<0.05 
 
PDAC* (1st degree) 12 9.9% 
 
13 5.3% 
 
0.10 
 
PDAC (2nd degree) 4 3.3% 
 
0 0.0% 
 
<0.05 
Common sites, first-degree family history 
       
 
Colorectal cancer 17 14.1% 
 
93 37.8% 
 
<0.001 
 
Gastric cancer 9 7.4% 
 
12 4.9% 
 
0.32 
 
Breast cancer 6 5.0% 
 
21 8.5% 
 
0.22 
 
Lung cancer 12 9.9% 
 
18 7.3% 
 
0.39 
 
Uterine cancer 3 2.5% 
 
4 1.6% 
 
0.69 
 
Melanoma 3 2.5% 
 
3 1.2% 
 
0.40 
 
Hepatocellular carcinoma 6 5.0% 
 
5 2.0% 
 
0.19 
Drugs 
       
 
Use of aspirin 16 13.2% 
 
34 14.3% 
 
0.78 
 
Use of statins 20 16.5% 
 
49 20.6% 
 
0.36 
 
Use of insulin 7 5.8% 
 
0 0.0% 
 
<0.001 
         
Data are mean (SD) for continuous variables or number of individuals (%) for discrete 
variables   
 
*PDAC=pancreatic ductal adenocarcinoma 
 
Cases were more frequently associated with history of chronic pancreatitis (p<0.001), 
diabetes mellitus (p<0.001), both insulin-dependent (p<0.001) and non-insulin 
dependent (p<0.05), as well as previous history of cholecystectomy (p<0.01) (Table 14). 
 35 
 
In regards to cancer family history, IPMN patients were significantly more likely to 
have 2nd-degree family history for any cancer (p<0.05), and 2nd-degree family history 
for PDAC (p<0.05). On the other hand, controls were significantly more likely to have a 
1st-degree relative with history of CRC (p<0.001) (Table 14).  
 
In all of the cases and controls entire colon was examined. Table 15 reports polyp 
findings among cases and controls according to colonoscopy. 
 
 
 
Table 15. Polyp findings among 122 patients with intraductal papillary mucinous neoplasms 
(IPMN)s of the pancreas and 246 controls according to colonoscopy  
 
  
Cases 
(n=122)   
Controls 
(n=246)   
p 
value 
Colon polyps 52 42.6% 
 
79 32.1% 
 
<0.05 
 
Adenomatous polyps 29 23.8% 
 
57 23.2% 
 
0.9 
 
Multiple adenomatous polyps 11 9.0% 
 
20 8.1% 
 
0.77 
 
Low grade dysplasia 24 19.7% 
 
48 19.5% 
 
0.98 
  High grade dysplasia 6 4.9%   11 4.5%   0.85 
         
Data are mean (SD) for continuous variables or number of individuals (%) for discrete 
variables   
 
 
Colorectal polyps were found in 52 IPMNs (42.6%) and in 79 controls (32.1%) 
(p<0.05) (Table 15). Mean polyp diameter was 6.1±5.28mm. In 29 cases (23.8%) and 
57 controls (23.2%) histological examination disclosed adenomatous polyps (p=0.90), 
which were multiple in 11 cases (9%) and 20 controls (8.1%) (p=0.77) (Table 15). 
There was no difference between the groups in regard to presence of polyps with low-
grade dysplasia (19.7% vs. 19.8%, p=0.98) or high-grade dysplasia (4.9% vs. 4.5%, 
p=0.85) (Table 15). 
 Three cases of CRC were detected, 2 among IPMNs (1.6%) and 1 among controls 
(0.4%), but the frequency was too small to make any comparison between the groups.  
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As we expected that 1st-degree family history of CRC might affect the prevalence of 
colorectal polyps, Table 16 reports the data stratified according to this covariate (Table 
16). 
 
 
Table 16. Prevalence of colon polyps in intraductal papillary mucinous neoplasms (IPMN)s of the 
pancreas cases and controls according to family history of colorectal cancer (CRC)  
1st-degree family history of CRC  Cases (n=104)   Controls (n=153)   p-value 
   
  
 
  
 
 
Colon polyps 45 43.4% 
 
48 31.4% 
 
0.051 
 
Adenomatous polyps 26 25.0% 
 
36 23.5% 
 
0.79 
 
Multiple adenomatous polyps 10 9.6% 
 
13 8.5% 
 
0.76 
 
Low grade dysplasia 21 20.2% 
 
30 19.6% 
 
0.90 
 
High grade dysplasia 8 7.7% 
 
8 5.2% 
 
0.88 
 
        No 1st-degree family history of CRC  Cases (n=17)  Controls (n=93)  p-value 
   
  
 
  
 
 
Colon polyps 6 35.3% 
 
31 33.3% 
 
0.85 
 
Adenomatous polyps 3 17.7% 
 
21 22.6% 
 
0.65 
 
Multiple adenomatous polyps 1 5.9% 
 
7 7.5% 
 
0.81 
 
Low grade dysplasia 3 17.6% 
 
18 19.3% 
 
0.85 
  High grade dysplasia 1 5.9%   3 3.2%   0.59 
Data are number of individuals (%) 
       
 
 
 
No significant difference in the prevalence of colorectal polyps or adenomatous polyps 
with low-grade or high-grade dysplasia was observed between IPMN cases and controls 
without 1st degree family history of CRC (Table 16). 
 However when restricting the analysis on cases and control with 1st degree family 
history of CRC only, we observed a borderline significantly higher prevalence of 
colorectal polyps among IPMN cases (43.3% vs. 31.4%, p=0.051) (Table 16). 
Nevertheless, when taking into consideration only adenomatous polyps, no significant 
difference between IPMN cases and controls with 1st degree family history of CRC was 
observed (Table 16). 
 
 37 
 
5. Discussion 
 
Our study is the first multicentric study of IPMNs conducted in Europe. Results show 
that 23.6% of IPMNs experience EPMs. The rate of prevalent EPMs was higher than 
expected from the general reference population, especially for CRC, renal cell and 
thyroid cancers. Additionally, we reported that increased age, alcohol consumption and 
1st-degree family history of gastric cancer are associated with the occurrence of any 
EPMs among IPMN patients, while 1st-degree family history of CRC was borderline 
significant. 
Number of authors so far addressed the association of IPMN with EPMs (Table 1). First 
study was conducted in 1999 by Sugiyama et al. (50). They conducted a study on 42 
patients who underwent surgery because of the IPMN, focusing on the incidence and 
characteristics of nonpancreatic neoplasms. Fifteen (32%) among them were reported 
with EPMs. Most frequently reported EPMs were CRC (11.9%) and gastric cancer 
(9.5%). Only risk factor significantly associated with occurrence of EPMs was age.  
Followed the study by Osanai et al. (51), conducted on 148 IPMN patients, including 
both those treated surgically and those not. Thirty-five patients (23.6%) experienced 
EPMs. Of those 11 were diagnosed with CRC (7.4%), 8 with gastric cancer (5.4%), and 
5 with lung cancer (3.4%). Similar study was conducted by Kamisawa et al. on 79 cases 
of IPMN diagnosed by detection of mucous in the pancreatic duct during ERCP (52). 
Forty EPMs occurred in 28 patients (35.4%). Major associated EPMs were gastric 
cancer (15.2%), CRC, (8.9%), esophageal cancer (5.1%) and lung cancer (5.1%). 
Development of EPMs was significantly related to age. Choi et al. (53) set up a study in 
order to estimate incidence and clinicopathological features of extrapancreatic 
neoplasms in patients with IPMN. They enrolled 61 patients who underwent surgical 
resection for IPMN. Twenty-four (39%) among them developed 26 extrapancreatic 
neoplasms, and 18 (30%) had EPMs. Gastric adenocarcinoma (33%) and CRC (17%) 
were reported to be the most common EPMs.  
Another study from Japan was conducted by Eguchi et al. (54). They screened the 
records of 69 surgically treated IPMN patients in order to assess the risk factors for 
preoperative or postoperative EPMs. This also was the first study trying to calculate the 
rate of increase of EPMs in IPMN patients, compared with the normal population. The 
O/E ratios were calculated by using the Osaka Cancer Registry. The preoperative EPMs 
 38 
 
were diagnosed in 38% of patients. Most frequently diagnosed was CRC (11.6%), 
followed by gastric cancer (5.8%). The O/E ratio of preoperative EPMs was 
significantly high in IMPN patients (2.41; 95% CI, 1.51-3.64). Furthermore O/E ratio 
for preoperative CRC was also significant (5.37; 95% CI, 2.31-10.58). Logistic 
regression analysis showed IPMN and age to be independent risk factors for 
preoperative CRC development. During the postoperative follow-up, 10 IPMN patients 
(15%) developed EPMs and 3 died from it. 
After these initial studies conducted in Asian population came the study by Riall et al. 
(55) conducted in the USA. They performed a population-based observational cohort 
study in order to determine the incidence and site of additional EPMs in patients with 
invasive IPMN. Noninvasive IPMNs were not included in the analysis. In order to 
obtain the data needed, they used Surveillance, Epidemiology, and End Results (SEER) 
tumor registry database. The registry is sponsored by the National Cancer Institute and 
contains over 3 million cancer cases, with 170.000 new cases added annually. Authors 
identified 992 case of invasive IPMN reported in the period 1973-2001. Among these, 
100 patients (10.1%) developed EPMs. The most frequent were CRC (2.5%), breast 
cancer (1.5%) and prostate cancer (1.4%). In addition, authors calculated the O/E ratio 
based on the 2006 Cancer Statistics and the 2005 estimated USA population for the 
USA Census Bureau. The observed rate of CRC was 1.66 times the rate expected in the 
general population. Rates of breast and lung cancer were also increased, with O/E ratios 
of 1.13 and 1.22, respectively. 
First study from European population was conducted in France by Baumgaertner et al 
(56). Authors set up a case–control study comparing 178 patients with resected IPMN 
with 356 age- and gender-matched controls in order to assess the association of IPMN 
with EPMs. Ninety-one of IPMN patients have been verified with hyperplasia/low-
grade dysplasia and 87 with high-grade dysplasia/invasive cancer. EPMs were found in 
30 of 178 (16.8%) patients with IPMN, 70% of which preceding IPMN. The most 
frequent EPMs in IPMN patients were breast cancer (5.4%), prostate cancer (2.2%) and 
CRC (1.7%). The grade of dysplasia in IPMN was not associated with EPM occurrence.  
What followed were another three studies from Asia, one from Japan (57) and two from 
South Korea (58, 59). Ishida et al. (57) conducted a study on 61 patient who underwent 
surgery because of IPMN in Tohoku University Hospital between 1988 and 2006. 
Thirty-six of these were diagnosed with intraductal papillary-mucinous carcinomas 
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including 6 with invasive carcinomas. Synchronous and metachronous EPMs were 
observed in 15 out of the 61 patient (24.6%). Among them gastric cancer was observed 
in 10% of IPMNs and CRC in 8%. None of the features, including sex, age, smoking, 
family history, macroscopic types (main duct type or branch duct type) and histological 
types (gastric, intestinal, pancreatobiliary or oncocytic) was associated with EPMs. 
However, EPMs were more frequent among malignant than benignant IPMNs. Oh et al. 
(59) reported from the small series of 37 IPMN patients confirmed either by surgical 
resection or typical findings of EUS and CT imaging. Ten (27%) IPMNs were 
associated with EPMs. Gastric cancer (3 patients, 8.1%) and CRC (3 patients, 8.1%) 
were the most common neoplasms. Finally the biggest study in Asian population so far 
was conducted by Yoon et al. (58). They aimed to assess the prevalence and associated 
factors of EPMs in IPMN patients and to compare it with those of non-IPMN pancreatic 
cystic neoplasm patients. Number of 210 IPMNs and 175 patients with other cystic 
neoplasm of the pancreas was included in the study. The prevalence of EPM was 33.8% 
for IPMNs and was significantly higher than in patients with other cystic neoplasms of 
pancreas. Most frequent among EPMs was gastric cancer (13.8%), followed by CRC 
(7.6%) and bile duct cancer (3.8%). Age was significantly associated with occurrence of 
EPMs in IPMN patients, while malignant IPMN showed a borderline inverse 
association.  
Another interesting study came from the Mayo Clinic. Reid-Lombardo et al. (60) 
identified all patients diagnosed with IPMN at the named institution from 1994 to 2006 
in order to estimate the frequency of EPMs and compare it to one in patients with ductal 
pancreatic cancer and a general referral population. Four hundred seventy one patients 
with IPMN were enrolled. Among them 40.8% were diagnosed with 192 EPMs before 
or coincident with IPMN. The most common EPMs were non-melanoma skin cancer 
(7.5%), breast cancer (5.1%), prostate cancer (5.1%), CRC (4.0%), and carcinoid 
neoplasms (1.3%). IPMN patients were at significantly higher risk to harbor 
hepatobiliar (OR: 3.0, 95% CI: 1.1–8.1), esophageal (OR: 5.5, 95% CI: 1.8–16.5), and 
gastrointestinal stromal tumors (OR: 3.8, 95% CI: 1.0–14.1) in compare to general 
referral population. Furthermore, occurrence of colonic polyps was registered in high 
number of IPMN cases (114, 24%). As IPMN patients were at significantly higher risk 
to develop colonic polyps (OR: 1.9, 95% CI: 1.4–2.4) authors suggested screening 
colonoscopy to be considered in all of them. 
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Lubecky et al. (61) reported the results originating from series of 82 patients diagnosed 
in single center in Israel. They intended to evaluate the association of IPMN with 
EPMs, but also to assess the influence of cancer family history and germline BRCA1 
and BRCA2 mutations to the named association. They reported EPMs in 19.6% of 
IPMN patients. Most frequent were CRC (6.1%), breast (3.7%) and prostate cancer 
(3.7%). There was an increased rate of cancer in families of IPMN patients; however 
this difference did not reach statistical significance. Nevertheless, a significantly higher 
rate of CRC in families of IPMN patients who had EPMs was observed. Based on these 
findings authors suggested a genetic component in the pathogenesis of IPMN. 
Furthermore, they suggested that possible genetic changes include BRCA2, as BRCA2 
mutations were found in 25% of IPMN patients with a family history of pancreatic 
cancer. 
Only study present in the moment of initiation of our study that took into consideration 
only incident EPMs was study by Kawakubo et al. (62). They conducted a study on 642 
Japanese IPMN patients in order to estimate the frequency of incident EPMs during the 
follow-up of 4.8 years on average. The incidence of the observed EPMs was compared 
with the expected incidence of the age- and gender-matched general Japanese 
population in order to calculate standardized incidence ratio (SIR). Forty EPMs 
developed in 39 patients (6.1%) during follow-up. The most common malignancies 
were hepatocellular (1.1%), colorectal (0.9%), gastric (0.9%), lung (0.8%) and prostate 
cancers (0.6%). They reported SIRs of 2.17 (95% CI 0.87-4.47) for hepatocellular 
cancer, 1.02 (95% CI 0.37-2.21) for CRC, 0.76 (95% CI 0.28-1.66) for gastric cancer, 
0.75 (95% CI 0.24-1.76) for lung cancer and 1.00 (95% CI 0.71-1.29) for prostate 
cancer. 
As can be seen, most of the studies available in the moment of initiation of our study 
were mainly in Asian populations (50-54, 57-59) (Table 1). Moreover most of the 
studies, included a small number of patients (<100) (50, 52-54, 57, 59), and many 
suffered of recruitment bias as IPMN patients were all surgical, thus including mainly 
malignant IPMNs (50, 53, 54, 57). These studies reported that the frequency of 
prevalent or incident EPMs was around 24.6%-38% (Table 1) (50, 53, 54, 57). 
Additional studies including surgical IPMNs and not, confirmed the higher frequencies 
of EPMs among IPMNs (52, 58, 59), with the largest study in Asian population (58) 
reporting a prevalence of EPMs of 33.8%. One study from US (60) reported a 
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prevalence of EPMs of 40.8% (60), while the only study conducted in Europe in the 
moment of initiation of our study reported an EPM occurrence of 16.8% (56). 
Unfortunately, most of these studies do not distinguish between prevalent and incident 
EPMs, so that results are hard to compare.  
Our results are consistent with what was previously published, as we reported that 
23.6% of IPMN patients experienced prevalent EPMs. Furthermore we showed 
significantly increased O/Es for CRC, renal cell carcinoma, thyroid and hematological 
cancers. Some authors before also tried to quantify the risk of EPMs in IPMN patients, 
comparing it to risk in control group (60) or general referral population (54, 55, 62). 
Eguchi et al. (54) showed a significantly increased O/E in the IPMN patients, especially 
for CRC. Rial et al. (55) reported increased risk for hepatobiliar, esophageal and 
gastrointestinal stromal tumors, and borderline significant risk for carcinoid and urinary 
tract tumors. Kawakubo et al. (62) performed long-term follow up of the IPMN patients 
and did not find any increased SIR of EPMs. Although in our study we diagnosed 5 
metachronous cancers, our follow-up was too short to calculate SIRs. The follow-up is, 
however, undergoing so that additional reports on the incident of EPMs in our cohort 
are expected.  
Two new studies on the subject were published recently by group of Marchegiani et al. 
(82, 83). They have put an accent on the incident EPMs in IPMN patients in order to 
calculate SIRs. Initially they conducted a study on 456 IPMN patients diagnosed at 
single center in Verona, Italy who were followed according to guidelines at a median 
follow-up of 56 months (82). The incidence of EPMs was calculated only in patients 
who were free of them at the time of IPMN diagnosis. Data were compared with Italian 
cancer statistics in order to calculate SIRs. Thirty EPMs developed during the follow-up 
with cumulative incidence of 6.6%. Authors reported SIR of 1.35 (95% CI, 0.91–1.93). 
After stratification according to gender SIR was 1.40 (95% CI, 0.72–2.45) in males and 
1.37 (95% CI, 0.81–2.16) in females. When the analysis was stratified by single tumors, 
authors observed a significantly increased incidence of melanoma in females (SIR 5.56; 
95% CI, 1.12–16.26). 
Subsequently, same group published multicentric study on 816 patients with IPMNs 
evaluated from 2000 through 2013 at 4 academic institutions in Europe for development 
of extrapancreatic neoplasms (83). The incidence of extrapancreatic neoplasms was 
compared with sex-specific, age-adjusted European cancer statistics in order to calculate 
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SIR. Among the 816 patients included in the incidence analysis, 50 developed an 
extrapancreatic neoplasm after a median time of 46 months from study enrollment. The 
authors reported SIR of 1.48 (95% CI, 0.94-2.22) in males and of 1.39 (95% CI 0.90-
2.05) in females.  
Having in mind results of these two studies (82, 83) Marchegiani study group concluded 
that patients with IPMN do not have a significantly higher incidence of extrapancreatic 
neoplasms than the general population. However, although these two studies are so far 
only prospective studies in European population reporting SIRs for EPMs in IPMN 
patients, their results should be interpreted with caution. Above all, both studies actually 
reported borderline risks for EPMs among IPMNs, as single-centre study from Verona 
reported SIR of 1.35 (95% CI, 0.91–1.93) for both genders (82) while multicentric study 
reported SIR of 1.48 (95% CI, 0.94-2.22) in males and of 1.39 (95% CI 0.90-2.05) in 
females (83). Furthermore in the first study authors reported significantly increased 
incidence of melanoma in females (82). If we have in mind that the follow-up in these 
studies was relatively short it could be a case that after a longer follow-up in the same 
cohort these result would not be borderline any more, but significant. Therefore, in 
order to estimate the association between IPMN and incident EPMs, longer follow-up is 
needed. Larger multicentric European studies with longer follow-up could give an 
answer to this question in the future. 
Several studies showed that patients with IPMN have an increased risk of EPMs 
compared to those with PDAC (50, 53, 54, 60, 61), even though this is not true for 
malignant IPMN (55). In fact several reports also suggest that an inverse association 
exists between IPMN malignant potential and EPM frequency (57, 58). This 
observation was confirmed also in our study, as EPMs were borderline more frequent in 
non-surgical IPMNs. IPMN is considered to be a precursor lesion for PDAC (84), and 
patients with IPMNs have been reported to be at the increased risk to develop coexistent 
PDAC (48). Our study showed an increased O/E ratio for PDAC in IPMNs, speaking in 
favor of the “precursor lesion” theory. Unexpectedly, however, we observed a 
protective effect of 1st-degree family history of PDAC to occurrence of EPMs in IPMN 
patients. As patients with 1st-degree family history of PDAC are reported to more likely 
develop PDAC (85), it is possible that the early onset of PDAC with aggressive 
progression could lead to insufficient time left for EPMs to occur. 
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Our study confirmed the role of increased age as risk factor for EPMs in IPMN (50, 52, 
55, 58), which is expected also in view of the well-known increased risk of cancer 
overall in older population (86). We identified 1st-degree family history of gastric 
cancer as a risk factor for EPMs, while 1st-degree family history of CRC was 
borderline. A recent study in Japan reported that individuals with 1st-degree family 
history of gastric cancer are at the increased risk to develop CRC (87), and this supports 
our finding as CRC is the second most common form of EPMs. Still, this result needs to 
be confirmed in a larger study, as it might be a peculiar finding only among the IPMN 
patients. First degree family history of CRC was reported as a risk factor for EPMs by 
Lubezky et al. (61), while another report implicated that IPMNs are associated with 
FAP syndrome (64). We were unable to find a significant association, though our 
borderline finding result is in line also with the knowledge that a large proportion of the 
EPMs are CRC, for which a positive family history is acknowledged (88). 
Concerning cigarette smoking habits, our study confirms that smoke is not associated 
with EPMs (53, 56), however we report that smokers who consumed ≥20 pack-years are 
more likely to have EPMs compared to <20 pack-years. Although alcohol has been 
previously investigated as a possible risk factor for EPMs among IPMNs (53, 56), our 
study is the first reporting a significant association. As alcohol has been reported as one 
of major contributors to cancer risk (89), it is conceivable that it can influence the 
occurrence of EPMs. For the first time we report a protective effect of peptic ulcer 
history towards EPMs in IPMNs, which need to be further investigated within studies 
that collected this information.  
Main limitation of this study is that we took into account only prevalent (synchronous 
and metachronous) and not incident EPMs. The follow-up of the patients was too short 
to refer also to incident EPMs and calculate SIR, so we limited our report only to O/E 
ratio generated from observed prevalent EPMs. However the follow-up is under way 
and it is expected that these results will be published in future. Diagnostic bias might be 
an issue, as EPMs might be overestimated in IPMN patients respect to the general 
population as these subjects are usually under increased medical observation. We feel, 
however, to exclude the presence of this bias as the vast majority of EPMs were 
diagnosed previous or concomitant with IPMN diagnosis, with IPMN actually 
diagnosed soon after the EPMs diagnosis.  
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The genetic association study we conducted did not find any of the named SNPs 
(rs6983267, rs6993464, rs7014346, rs10505477) in human chromosomal region 8q24 to 
be associated with IPMN. 
Since IPMN was reported to be associated with an increased risk of developing EPMs 
(51-61), especially CRC (50-54, 58, 59, 61), it has been hypothesized that common 
genetic background is responsible for the observed association. Lubecky et al. (61) 
found an increased rate of cancer in families of IPMN patients, specifically CRC. Based 
on these findings they suggested a genetic component in the pathogenesis of IPMN. 
Furthermore authors hypothesized that possible genetic changes include BRCA2. 
Nevertheless, none study so far ever attempted to test the hypothesis of the genetic 
background of the association between IPMN and EPMs. 
SNPs in human chromosomal region 8q24 are reported to be associated with cancer in 
general and, particularly, CRC (70). The majority of these associations lie at 
approximately 128 Mb on chromosome 8. Some of the SNPs have been shown to 
interact with the proto-oncogene MYC (68). MYC is an important protooncogene, over-
expressed in numerous tumors, including CRC. The region contains several other genes 
which could be functionally related to cancer development, including NOV and 
ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2). NOV encodes a 
regulatory protein from the CCN family that has been associated with cancer 
development (69). ENPP2 encodes a phospholipase which stimulates tumor cell motility 
and proliferation (90). In addition it has been reported (91) that both NOV and ENPP2 
are indirectly regulated by the 8q24 proto-oncogene MYC, via p53 (for NOV) (92, 93) 
and ESR2 (for ENPP2) (94, 95), what makes their potential involvement in a pathway 
for cancer susceptibility plausible. In light of the named facts, it can be supposed that 
this region contains a locus for general cancer susceptibility. 
Recent studies have identified and confirmed associations of several SNPs within the 
region with CRC (66, 96, 97), breast (98, 99) and prostate cancer (100-103). Additional 
associations have been found for kidney, thyroid, and larynx cancer (104), as well as 
cancer of the upper aerodigestive tract (105). Three regions of 8q24 in section of 430Mb 
were initially found to be associated with prostate cancer, while two additional regions 
have been identified recently (106, 107). As for CRC, statistically significant 
associations are reported in an approximately 60 kb region of high linkage 
disequilibrium between chromosomal location 128.475 and 128.545 Mb (108). 
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In light of previously mentioned facts we identified 8q24 region as a good starting point 
in an initial research in order to enlighten genetic background of an association between 
IPMN and EPMs. Nevertheless, financial limitations did not make possible to 
investigate all the SNPs in the region, thus we needed to choose some of them. We 
judged that SNPs rs6983267, rs6993464, rs7014346, rs10505477 are most likely to be 
present in IPMN patients. 
The SNP within 8q24 chromosome that so far showed highest significance for 
carcinogenesis and CRC in particular is rs6983267. There were several reports 
providing insights into the functional role of the rs6983267 (68, 109). Tuupanen et al. 
(109) reported that the risk allele G of rs6983267 shows copy number increase during 
CRC development. Furthermore, they showed that the SNP is located in a 
transcriptional enhancer and that the G allele has increased affinity for binding 
transcription factor 4 (TCF4) (109). The TCF4 is important in activating the 
transcription of Wnt target genes. Finally, they showed that the rs6983267 region 
physically interacts with the MYC promoter region (109). Based on these findings it can 
be concluded that the biological mechanisms associating the rs6983267 SNP to risk of 
CRC includes an impact on Wnt signalling and MYC expression (68, 109). 
Number of studies so far addressed the impact of rs698267 to CRC risk (67, 70, 97, 
103, 104, 110-117). All of them reported significant association of rs698267 with CRC. 
Hutter et al. (108) confirmed these findings by reporting modest but significant 
association (OR = 1.10; 95% CI: 1.01-1.20). Furthermore they conducted a meta-
analysis including all the trials available in the moment, and the association was 
confirmed one more time as they reported OR of 1.21 (95% CI: 1.18-1.24). Newer 
meta-analyses by Brisbin et al. (118) confirmed these findings. Howevers they reported 
rs698267 to be associated not only to CRC but also to prostate cancer. 
Aside from association of rs6993464 with CRC and prostate cancer, Brisbin et al. (118) 
also reported a novel SNP rs6993464, to be associated with cancer risk (p = 1.25E-07). 
The T allele of the SNP was associated with cancer risk in breast and pancreatic cancer 
(118). This SNP lies in the region between NOV and ENPP2. Several of the significant 
SNPs in this region are identified as expression quantitative trait loci (eQTLs) for genes 
throughout the genome being associated with various types of cancer (119). Among 
them rs6993464 has been shown to be an eQTL for POLR2F, a gene on chromosome 22 
which is up-regulated in CRC (120). 
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The SNP rs7014346 on chromosome 8q24, is located on the POU class 5 homeobox 1 
pseudogene 1 gene (POU5F1P1) (121). It has been suggested that that deregulated 
expression of POU genes in breast cancer cells could repress the expression of a tumor 
suppressor and activate the expression of an oncogenic growth factor (122). This SNP 
has been associated with increased risk to CRC (65, 108, 116) 
The SNP rs10505477 is located in the intron of Cancer Susceptibility Candidate 8 
(CASC8), a long non-coding RNA (lncRNA), which overlaps POU5F1B gene (123). It 
has been hypothesized that rs10505477 may disrupt the key regulatory region of 
CASC8, resulting in its miss-expression (123). In Miss-expressed CASC8 may 
modulate the recruitment of general transcription factors on the promoter of its cognate 
gene, POU5F1B, which was found to be a putative cancer susceptibility gene (124). By 
altering the fine turning interactions between the CASC8 and POU5F1B, the 
rs10505477 could be influencing cancer susceptibility (123). The rs10505477 has so far 
been associated with risk of CRC and breast cancer (66, 97, 125-127). Furthermore, Ma 
et al. (123) reported rs10505477 to be associated with the significantly lower survival 
rate in gastric cancer patients. 
These findings gave a strong rationale to our decision to select the named SNPs to be 
tested for the association with IPMN. However, the results of our study show that none 
of the selected SNPs from 8q24 regions is significantly associated with IPMN, even 
when stratified according to 1st-degree family history of cancer.  
Nevertheless in interpreting the results should be taken into consideration that due to 
relatively small number of included IPMN cases our study had limited power to identify 
weak but significant associations. Larger studies to come are needed in order to confirm 
our findings. Although we bring negative results, this is the first study addressing the 
genetic background of an association between IPMN and EPMs. Our finding should 
help other researchers to point their research in right direction, in order to further 
enlighten this subject. 
We conducted a case-control study in order to evaluate the prevalence of colorectal 
adenomas in prospectively enrolled Italian patients with IPMN undergoing first time 
screening colonoscopy. Compared to a matched control population of individuals who 
underwent colonoscopy for screening or for evaluation of non-specific abdominal 
symptoms, no increase prevalence of adenomatous polyps was found in IPMN patients. 
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This result did not show an increased propensity to develop colorectal adenomas among 
IPMN patients. 
CRC has been the most frequent EPM consistently found in IPMN patients (50-54, 58, 
59, 61). Eguchi et al. (54) reported that IPMN is a strong independent risk factor for 
preoperative CRC. They found that CRC occurred 5.37 times more frequently in IPMN 
patients than in the general population. Rial et al. (55) reported 1.66 times higher rate of 
CRC in patients with invasive IPMN as compared to USA general population. In 
multicentric hospital-based study, that is also part of this thesis, we reported that IPMN 
patients in Italy harbor CRC 2.26 times more frequently than expected. Furthermore, 
Lubezky et al. (61) reported that first degree family history of CRC is a risk factor for 
EPMs in IPMN patients. Another report implicated that IPMNs are associated with FAP 
syndrome (64).  
The mechanism(s) for the association between IPMN and CRC has not been elucidated 
so far. One important point has been raised by a study of Reid-Lombardo et al. (60), 
who performed a large case-control retrospective study at the Mayo Clinic. They found 
adenomatous colorectal polyps to be present 2 and 1.4 times more frequently in patients 
with IPMN as compared to patients with pancreatic adenocarcinoma and to the general 
population, respectively. These findings prompted the authors to advocate screening 
colonoscopy for all patients with IPMN.  
The adenoma-carcinoma sequence is a well-known carcinogenetic mechanism that is 
responsible for almost all sporadic CRCs (76). Colorectal adenomas are benign tumors 
that arise from the glandular epithelium and project themselves above the surrounding 
mucosa. They are characterized by dysplastic morphology and altered differentiation of 
the epithelial cells in the lesion (128). Individuals in whom colorectal adenomas are not 
removed are at the increased risk for CRC and colonoscopic polypectomy lowers that 
risk substantially (129). Residuals of adenomatous tissue are often observed in CRC 
specimens and individual foci of carcinoma can be detected in adenomatous polyps 
(130). Individuals affected by conditions that include increased propensity to harobour 
colorectal adenomas, such as FAP, hereditary nonpolyposis colorectal cancer or Lynch 
syndrome, almost inevitably develop CRCs by third to fifth decade of their life if their 
colon is not removed (131, 132). CRC develops from the progressive transformation of 
adenomatous polyps through a series of molecular events. The initial step is loss of 
adenomatous polyposis coli (APC), that leads to adenoma formation (133). What 
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follows are the mutations in the small GTPase KRAS, acquired by larger adenomas and 
early carcinoma, followed by loss of chromosome 18q with SMAD4, which is 
downstream of transforming growth factor-β (TGFβ), and mutations in TP53 in frank 
carcinoma (133). 
Based on this well-known mechanism and the results of the study by Reid-Lombardo et 
al. (60), we performed a study to test the hypothesis that the risk of CRC development 
in patients with IPMN could be related to an increased propensity to harbor colorectal 
adenomas. Differently from the study by Reid-Lombardo et al. (60) that was based on a 
retrospective chart review with possible bias toward an increased prevalence of 
adenomatous polyps in cases because of an increased probability of undergoing 
diagnostic test including colonoscopy, we evaluated the prevalence of colorectal polyps 
among a large cohort of consecutively enrolled patients with IPMN undergoing first 
time colonoscopy. As compared with a matched control population also undergoing first 
time colonoscopy for screening purposes or to evaluate non-specific symptoms, we 
found a higher prevalence of colorectal polyps among IPMN patients. When 
considering adenomatous polyps only, however, this difference was no longer 
significant. Furthermore, these results were confirmed after stratifying according to the 
1st-degree family history of CRC, which might affect the presence of colorectal 
adenomas. Therefore our study did not confirm the findings of Reid-Lombardo et al. 
(60). However, when interpreting our results should be kept in mind that Reid-
Lombardo et al. (60) included more MD-IPMNs and C-IPMNs. It could be a case that 
patients harboring these more invasive IPMN forms are more prone to develop 
colorectal adenomas. 
Overall, the results of our study suggest that factors other than an increased propensity 
of IPMN patients to harbor colorectal adenomas should be responsible for the increased 
occurrence of CRC in these patients. It could be hypothesized that the mechanism for an 
increased risk of CRC in IPMN might be an accelerated adenomas formation, as seen in 
patients with HNPCC.  
We observed several risk factors associated with IPMN. History of diabetes, use of 
insulin and history of chronic pancreatitis has been previously reported to be associated 
with IPMN (77). We found an association between cholecystectomy and IPMN, which 
has never been reported before and the meaning of which appears of an unclear value. 
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We acknowledge that our study has some limitations. It included a relatively limited 
number of IPMN cases, and because of small number of CRCs detected, it was 
underpowered to detect difference in CRC occurrence as compared to matched controls. 
However, the study was designed to assess the prevalence of adenomas and not CRC 
among IPMN. Furthermore, significantly higher rate of chronic pancreatitis and heavy 
drinking in the IPMN group suggests misclassification indicating that some of the cystic 
lesions may be pseudocysts rather than IPMNs. However, this is the first study 
assessing the prevalence of colorectal adenomas in IPMN patients at first time 
colonoscopy. Although the results reported were against our prior hypothesis of higher 
prevalence of colorectal adenomas among IPMN than the control population, our study 
highlighted the need to further explore the issue of association between IPMN and 
CRC. 
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6. Conclusions 
 
1. Patients with intraductal papillary mucinous neoplasms of pancreas are at higher 
risk of developing colorectal cancer than general population of Italy.  
2. Patients with intraductal papillary mucinous neoplasms of pancreas are at higher 
risk of developing renal cell carcinoma than general population of Italy. 
3. Patients with intraductal papillary mucinous neoplasms of pancreas are at higher 
risk of developing thyroid carcinoma than general population of Italy.  
4. Further investigations in other European populations are expected in order to 
confirm these findings. 
5. Systematic surveillance of intraductal papillary mucinous neoplasms cases for 
the colorectal, renal cell and thyroid carcinoma is advised.  
6.  Increased age, heavy cigarette smoking and alcohol consumption are significant 
risk factors for extrapancreatic malignanices in patients with intraductal 
papillary mucinous neoplasms of pancreas. 
7. First degree family history of gastric cancer is significant risk factors for 
extrapancreatic malignanices in patients with intraductal papillary mucinous 
neoplasms of pancreas.  
8. Further research are needed in order to fully enlighten the role of first degree 
family history of colorectal carcinoma as a risk factor for extrapancreatic 
malignanices in patients with intraductal papillary mucinous neoplasms of 
pancreas. 
9. Intraductal papillary mucinous neoplasms of the pancreas are not associated 
with single nucleotide polymorphisms rs6983267, rs6993464, rs7014346, 
rs10505477 within human chromosomal region 8q24.  
10. Further research are needed in order to examine if other single nucleotide 
polymorphisms within the human chromosomal region 8q24 are associated with 
intraductal papillary mucinous neoplasms of the pancreas. 
11. Patients with intraductal papillary mucinous neoplasms of pancreas are not in an 
increased risk for development of adenomatous colorectal polyps.  
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